Tempus AI, Inc. (NASDAQ:TEM) Director Sells $25,922.20 in Stock

Tempus AI, Inc. (NASDAQ:TEM) Director David R. Epstein sold 620 shares of the company’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $41.81, for a total transaction of $25,922.20. Following the completion of the sale, the director now directly owns 27,894 shares of the company’s stock, valued at $1,166,248.14. This represents a 2.17 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Tempus AI Stock Down 2.4 %

Shares of TEM stock opened at $41.00 on Monday. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. The stock’s 50-day moving average is $52.64. Tempus AI, Inc. has a 1-year low of $22.89 and a 1-year high of $79.49.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on TEM. Bank of America upped their price objective on shares of Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a report on Friday. Loop Capital upped their price objective on shares of Tempus AI from $48.00 to $57.00 and gave the company a “buy” rating in a report on Tuesday, October 15th. Stifel Nicolaus lowered shares of Tempus AI from a “buy” rating to a “hold” rating and upped their price objective for the company from $45.00 to $65.00 in a report on Monday, November 11th. Guggenheim began coverage on shares of Tempus AI in a report on Monday, December 9th. They issued a “buy” rating and a $74.00 price objective for the company. Finally, Wolfe Research began coverage on shares of Tempus AI in a report on Friday. They issued an “outperform” rating and a $60.00 price objective for the company. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, Tempus AI currently has a consensus rating of “Moderate Buy” and an average price target of $56.00.

Institutional Trading of Tempus AI

Several hedge funds have recently made changes to their positions in TEM. First Horizon Advisors Inc. acquired a new stake in shares of Tempus AI during the third quarter worth about $30,000. Sandia Investment Management LP acquired a new stake in shares of Tempus AI during the second quarter worth about $136,000. Vestor Capital LLC acquired a new stake in shares of Tempus AI during the third quarter worth about $153,000. Stifel Financial Corp acquired a new stake in shares of Tempus AI during the third quarter worth about $218,000. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd acquired a new stake in shares of Tempus AI during the third quarter worth about $258,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.